Perhaps more than any other Wolfestone client group, the pharmaceuticals sector requires precision and accuracy in all services.  This applies globally, but with dramatic growth projected in the Middle East and North Africa (MENA) this region in particular needs to be serviced in the most ethical, professional way possible.

 Although, it currently accounts for only 1.5% of the global pharmaceutical market, MENA demand is growing rapidly.  Since 2005, healthcare spending in the region has been rising at an average annual rate of approximately 15%.  According to Business Monitor International (BMI), the MENA pharmaceutical market will be worth $23.7 billion by 2014.

The road map for servicing this growing requirement is unlikely to follow straight lines, but by trading ethically and building a solid partnership network, suppliers can add value for themselves and provide crucial services where they’re most needed.

The MENA region’s healthcare systems don’t yet have a tried and tested mechanism for providing universally accessible healthcare of suitable cost and quality. Without a long term blueprint in place, the need for effective ad hoc services is all the more pressing.  Responsible service providers are continuously looking for ways to combat market shortage, paving the way for better, faster critical patient care.

The issues in the MENA region are familiar to industry insiders.  Successful hospital supply chain management is crucial, and all prospective providers need to establish themselves as trustworthy partners, prioritising the importance of high quality care to gain credibility and trust with clinicians.  Clear, properly pitched communication is crucial, and more and more Wolfestone clients are localising their websites, technical documents and marketing material as well as their business-critical clinical data.

One Wolfestone partner that has reached out to the MENA region with increasing success is Ellis Pharma.  Renowned as a supplier to, among others, the British Armed Forces, they provide vital supplies for running hospitals, replenishing medical kits and whatever else is required, giving their clients the tools to do their jobs in all situations.

Ellis Pharma understands the need for communication and partnership at all levels.  Through building strong relationships with pharmaceutical manufacturers and product sourcing partners around the world, they have a proven mechanism for meeting regional market shortages swiftly and precisely.  Ellis Pharma have avoided the wholesale route for exports, and by focusing instead on the option of small, specific orders for a single drug, they can supply exactly what’s required without tying customers in to unnecessary repeat orders.  They give their customers what they need, no more and no less.  The result?  Better, faster critical patient care.  Put simply, their approach saves lives.

Wolfestone sees Ellis Pharma as an ideal export partner.  A company with a well-earned reputation for innovation that delivers crucial services in exactly the measure required, they’ve added value to businesses and lives across the globe. For the MENA region in particular, their ability to deliver “ad hoc” with absolute precision could hardly be timelier or more valuable.  If the demand for pharmaceutical supplies in the Middle East and North Africa continues to grow as forecast we believe Ellis Pharma’s reputation will grow with it, and we’re delighted to be working alongside them.

 DAVID JONES

 

For more information about Wolfestone services:

Document translation servicesLocalisation servicesTranscreation servicesMultilingual SEO servicesProofreadingVoiceover servicesInterpreting servicesMultimedia servicesLegal translation servicesOther types of translation

The professional translation services you can trust!

  • Amita Sharma

    I am in agreement about the economic and ethics discussed here. It is only my regret that this strategy is focussing on MENA and not on India. The Indian share of pharma market is growing fast and we will be depending heavily on foreign support. This is made more urgent because there is an issue with skilled and qualified people domestically to work in the sector. I am finding that skilled young people are more attracted to careers in Information Technology, where they can have more money and be practising within a more established infrastructure. But without them we will never have the infarstructure! This is not a problem for Ellis Pharma to solve and it is a benefit of course that faster critical patient care is available from them.

  • Adele Marinescu

    It is not only Middle East & North Africa that needs critical patient care. Europe has many layers of healthcare and it is a frustration that tax laws are providing an obstruction to Pharmaceuticals companies working in my country. To support Romania’s healthcare system we demand “claw back” tax on their revenues. It is also a big problem that it takes a long time to approve a new product for official inclusion on the list of compensated medicines. I think this is a barrier even more to “ad hoc” services you are describing here and that is harmful, because this method of sending what exactly is needed is clearly an aid to speed and economy.

  • Paul Chammings

    This provision of ad hoc services fits in with the pattern of dealing with broader social issues in the MENA region such as civil unrest and population movements. By offering a swift, targeted service along the lines that you’ve described, Ellis appears to be echoing the best practice of charities such as the Red Cross and Red Crescent. I almost fell of my chair as I finished that last sentence. I’m unaccustomed to comparing pharma companies with humanitarian charities but based on the facts it’s not an outlandish comparison.

  • Chiumbo Wangai

    This approach for MENA is strong, making partnerships locally for fast care is excellent. I hope this will also extend to central/east africa because typically a hospital in such a region may be a hub with satellite facilities to help remote places, so fast action and distribution for the quantities required must add value.

  • Ellis Pharma is a dedicated supplier of the commercial pharmaceutical product. We specialize in meeting regional market shortage across the full International sector where regulatory compliance allows.

    We understand that there are pharmaceutical requirements and shortages being experienced all over the world, and with direct manufacturer support and our regulatory compliant solution, we aim to deliver.

    Our main objective is now, and always will be, the patient that is in need of continuous critical care and treatment.

    We are, in Ellis Pharma, fortunate to have excellent relationships with manufacturers that enhance our offer in terms of pricing and supply capabilities.